You are here: Home » PTI Stories » National » News
Business Standard

Lupin launches generic Axiron topical solution in US

Press Trust of India  |  New Delhi 

Drug firm today said it has launched its in the American market.

The company has launched Topical Solution, 30 mg per actuation, in the US after receiving approval from the Food and Drug Administration (USFDA), said in a filing to BSE.

The company's product is the generic version of and the companys Axiron topical solution, 30 mg per actuation, it added.

It is indicated for replacement therapy in males for conditions associated with or absence of endogenous testosterone, said.

As per IQVIA MAT December 2017 data, topical solution, 30 mg per actuation had annual sales of approximately USD 179 million in the US, it added.

Shares of Lupin today closed at Rs 821.30 per scrip on BSE, up 1.75 per cent from the previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, February 26 2018. 16:25 IST